Trials / Completed
CompletedNCT00711165
Mometasone and Markers of Airway Inflammation
The Effects of Mometasone on Markers of Airway Inflammation
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Creighton University · Academic / Other
- Sex
- All
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.
Detailed description
Patients with asthma and not treated with anti-inflammatory medications were studied. This was a parallel, randomized, placebo-controlled study to investigate the effects of Asmanex on markers of airway inflammation including exhaled nitric oxide, airway reactivity, FEV1 and nitrates/nitrites and pH in exhaled breath condensate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | 2 puffs, qd |
| DRUG | Mometasone Furoate | 400 mcg, qd for 8 weeks |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2006-04-01
- Completion
- 2006-08-01
- First posted
- 2008-07-08
- Last updated
- 2008-07-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00711165. Inclusion in this directory is not an endorsement.